Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Financial Performance - Sage Therapeutics reported a quarterly loss of $0.79 per share, better than the Zacks Consensus Estimate of a loss of $0.96, and an improvement from a loss of $1.7 per share a year ago, representing an earnings surprise of +17.71% [1] - The company posted revenues of $31.66 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 80.91%, compared to revenues of $8.65 million in the same quarter last year [2] - Over the last four quarters, Sage Therapeutics has surpassed consensus revenue estimates two times [2] Stock Performance - Sage Therapeutics shares have increased approximately 60.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.79 on revenues of $26.88 million, and for the current fiscal year, it is -$3.65 on revenues of $82.09 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Sage Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]